These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 11068018

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Peroxisome proliferator-activated receptor-gamma activation inhibits interleukin-1beta -mediated platelet-derived growth factor-alpha receptor gene expression via CCAAT/enhancer-binding protein-delta in vascular smooth muscle cells.
    Takata Y, Kitami Y, Okura T, Hiwada K.
    J Biol Chem; 2001 Apr 20; 276(16):12893-7. PubMed ID: 11278956
    [Abstract] [Full Text] [Related]

  • 4. Peroxisome proliferator-activated receptor (PPAR)-gamma expression in human vascular smooth muscle cells: inhibition of growth, migration, and c-fos expression by the peroxisome proliferator-activated receptor (PPAR)-gamma activator troglitazone.
    Benson S, Wu J, Padmanabhan S, Kurtz TW, Pershadsingh HA.
    Am J Hypertens; 2000 Jan 20; 13(1 Pt 1):74-82. PubMed ID: 10678274
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes.
    Sugawara A, Takeuchi K, Uruno A, Ikeda Y, Arima S, Sato K, Kudo M, Taniyama Y, Ito S.
    Hypertens Res; 2001 May 20; 24(3):229-33. PubMed ID: 11409645
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells.
    Takeda K, Ichiki T, Tokunou T, Funakoshi Y, Iino N, Hirano K, Kanaide H, Takeshita A.
    Circulation; 2000 Oct 10; 102(15):1834-9. PubMed ID: 11023940
    [Abstract] [Full Text] [Related]

  • 10. Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-gamma.
    Park KS, Ciaraldi TP, Lindgren K, Abrams-Carter L, Mudaliar S, Nikoulina SE, Tufari SR, Veerkamp JH, Vidal-Puig A, Henry RR.
    J Clin Endocrinol Metab; 1998 Aug 10; 83(8):2830-5. PubMed ID: 9709955
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Peroxisome proliferator-activated receptor gamma ligands inhibit mitogenic induction of p21(Cip1) by modulating the protein kinase Cdelta pathway in vascular smooth muscle cells.
    Wakino S, Kintscher U, Liu Z, Kim S, Yin F, Ohba M, Kuroki T, Schönthal AH, Hsueh WA, Law RE.
    J Biol Chem; 2001 Dec 14; 276(50):47650-7. PubMed ID: 11598137
    [Abstract] [Full Text] [Related]

  • 17. Ligand activation of peroxisome proliferator-activated receptor gamma induces apoptosis of leukemia cells by down-regulating the c-myc gene expression via blockade of the Tcf-4 activity.
    Yamakawa-Karakida N, Sugita K, Inukai T, Goi K, Nakamura M, Uno K, Sato H, Kagami K, Barker N, Nakazawa S.
    Cell Death Differ; 2002 May 14; 9(5):513-26. PubMed ID: 11973610
    [Abstract] [Full Text] [Related]

  • 18. Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-gamma-mediated changes in gene expression.
    Brunmair B, Gras F, Neschen S, Roden M, Wagner L, Waldhäusl W, Fürnsinn C.
    Diabetes; 2001 Oct 14; 50(10):2309-15. PubMed ID: 11574413
    [Abstract] [Full Text] [Related]

  • 19. Troglitazone and pioglitazone attenuate agonist-dependent Ca2+ mobilization and cell proliferation in vascular smooth muscle cells.
    Asano M, Nakajima T, Iwasawa K, Morita T, Nakamura F, Imuta H, Chisaki K, Yamada N, Omata M, Okuda Y.
    Br J Pharmacol; 1999 Oct 14; 128(3):673-83. PubMed ID: 10516648
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.